Drawing for MYCO-DIGITAL

USPTO serial 79418319

MYCO-DIGITAL

Reviewed by CopyMark Law Group

Reg. 8217373Status 700Registered
Filing date
Status date
Registration date
Apr 21, 2026
Examiner
CARUSO, JAMES J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MYCO-DIGITAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey A. Smith

Jeffrey A. Smith Millen White Zelano and Branigan PC2200 Clarendon Blvd Suite 1400Arlington, VA 22201United States

Goods and services

ClassDescriptionStatusFirst use
005Chemical preparations for medical use for mycoplasma detection in cell cultures for use in cell therapy and regenerative medicine; chemical preparations for medical use, namely, media for cell cultures for medical use in the field of cell therapy quality control; pharmaceutical products containing cultured cells for cell therapy quality control; veterinary products, namely, culture media for cultivating animal cells for veterinary use in the field of animal cell therapy quality controlACTIVE—
042Scientific research; technological research for mycoplasma detection in the field of cell cultures, cell therapy and regenerative medicine and related manufacturing processes, medical instruments and pharmaceutical studies; computer software design for mycoplasma testing analyses; computer software development for mycoplasma testing analyses; research and development of new products for third parties; conducting of technical project studies, namely, scientific studies in the field of new technologies for cell cultures, cell therapy and regenerative medicine and scientific feasibility studies; computer software installation; computer software maintenance; updating of computer software; rental of computer software for mycoplasma testing analyses; Software as a Service (SaaS) services featuring software for use in mycoplasma testing analysesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 15, 2026FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 28, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 28, 2026FIMPFINAL DISPOSITION PROCESSED—
Aug 20, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Aug 5, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 5, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jul 21, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 21, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 21, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 3, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 3, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 25, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 4, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 4, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Feb 4, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 4, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 4, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 29, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Jan 29, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 29, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 29, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 15, 2026ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jan 15, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 15, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 15, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 15, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Aug 29, 2025RFNTREFUSAL PROCESSED BY IB—
Aug 12, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 12, 2025RFRRREFUSAL PROCESSED BY MPU—
Jun 28, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 27, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 23, 2025DOCKASSIGNED TO EXAMINER—
Mar 28, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 28, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 25, 2025LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Mar 6, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance